$EHC
Encompass Health Corp Stock $ehc

$ehc Overview Financials Valuation SEC Filings Company Website

2015 Q2 Form 10-Q Financial Statement

#000078516115000069 Filed on July 30, 2015

Income Statement

Concept	2015 Q2	2014 Q2
Revenue	$764.4M	$604.4M
YoY Change	26.47%	7.07%
Cost Of Revenue	$31.70M	$27.80M
YoY Change	14.03%	4.51%
Gross Profit	$721.8M	$567.3M
YoY Change	27.23%	6.86%
Gross Profit Margin	94.43%	93.86%
Selling, General & Admin	$446.5M	$327.8M
YoY Change	36.21%	3.34%
% of Gross Profit	61.86%	57.78%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$32.70M	$26.40M
YoY Change	23.86%	14.29%
% of Gross Profit	4.53%	4.65%
Operating Expenses	$583.4M	$439.7M
YoY Change	32.68%	4.87%
Operating Profit	$123.4M	$127.6M
YoY Change	-3.29%	14.34%
Interest Expense	-$28.60M	-$25.20M
YoY Change	13.49%	19.43%
% of Operating Profit	-23.18%	-19.75%
Other Income/Expense, Net	$3.000M	$28.20M
YoY Change	-89.36%	1384.21%
Pretax Income	$94.00M	$130.6M
YoY Change	-28.02%	41.34%
Income Tax	$32.20M	$36.50M
% Of Pretax Income	34.26%	27.95%
Net Earnings	$42.90M	$83.10M
YoY Change	-48.38%	-49.7%
Net Earnings / Revenue	5.61%	13.75%
Basic Earnings Per Share	$0.47	$0.93
Diluted Earnings Per Share	$0.45	$0.85
COMMON SHARES
Basic Shares Outstanding	89.80M shares	86.70M shares
Diluted Shares Outstanding	101.5M shares	100.6M shares

Balance Sheet

Concept	2015 Q2	2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$45.50M	$65.80M
YoY Change	-30.85%	-4.22%
Cash & Equivalents	$45.50M	$65.80M
Short-Term Investments
Other Short-Term Assets	$126.7M	$103.9M
YoY Change	21.94%	-6.9%
Inventory
Prepaid Expenses
Receivables	$351.8M	$272.3M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$712.4M	$580.9M
YoY Change	22.64%	-1.79%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.063B	$976.5M
YoY Change	8.84%	23.09%
Goodwill	$1.098B	$34.80M
YoY Change	3053.74%	154.01%
Intangibles	$325.5M	$103.3M
YoY Change	215.1%	19.01%
Long-Term Investments
YoY Change
Other Assets	$191.6M	$148.0M
YoY Change	29.46%	7.17%
Total Long-Term Assets	$2.757B	$1.996B
YoY Change	38.16%	3.93%
TOTAL ASSETS
Total Short-Term Assets	$712.4M	$580.9M
Total Long-Term Assets	$2.757B	$1.996B
Total Assets	$3.470B	$2.577B
YoY Change	34.66%	2.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$60.00M	$55.70M
YoY Change	7.72%	-2.79%
Accrued Expenses	$283.2M	$243.6M
YoY Change	16.26%	-4.21%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$21.40M
YoY Change
Total Short-Term Liabilities	$364.6M	$299.3M
YoY Change	21.82%	-3.95%
LONG-TERM LIABILITIES
Long-Term Debt	$2.104B	$1.475B
YoY Change	42.66%	11.78%
Other Long-Term Liabilities	$137.3M	$141.1M
YoY Change	-2.69%	7.38%
Total Long-Term Liabilities	$137.3M	$141.1M
YoY Change	-2.69%	7.38%
TOTAL LIABILITIES
Total Short-Term Liabilities	$364.6M	$299.3M
Total Long-Term Liabilities	$137.3M	$141.1M
Total Liabilities	$2.606B	$1.916B
YoY Change	36.06%	8.67%
SHAREHOLDERS EQUITY
Retained Earnings		-$1.971B
YoY Change		-10.73%
Common Stock		$1.000M
YoY Change		0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)		$457.6M
YoY Change		13.27%
Treasury Stock Shares		16.24M shares
Shareholders Equity	$605.9M	$413.7M
YoY Change
Total Liabilities & Shareholders Equity	$3.470B	$2.577B
YoY Change	34.66%	2.58%

Cashflow Statement

Concept	2015 Q2	2014 Q2
OPERATING ACTIVITIES
Net Income	$42.90M	$83.10M
YoY Change	-48.38%	-49.7%
Depreciation, Depletion And Amortization	$32.70M	$26.40M
YoY Change	23.86%	14.29%
Cash From Operating Activities	$102.9M	$128.0M
YoY Change	-19.61%	21.44%
INVESTING ACTIVITIES
Capital Expenditures	-$34.90M	-$36.90M
YoY Change	-5.42%	-13.58%
Acquisitions		$15.90M
YoY Change		-44.98%
Other Investing Activities	-$46.10M	-$2.300M
YoY Change	1904.35%	-78.7%
Cash From Investing Activities	-$81.00M	-$39.20M
YoY Change	106.63%	-26.73%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-184.7M	-76.10M
YoY Change	142.71%	20.22%
NET CHANGE
Cash From Operating Activities	102.9M	128.0M
Cash From Investing Activities	-81.00M	-39.20M
Cash From Financing Activities	-184.7M	-76.10M
Net Change In Cash	-162.8M	12.70M
YoY Change	-1381.89%	-211.4%
FREE CASH FLOW
Cash From Operating Activities	$102.9M	$128.0M
Capital Expenditures	-$34.90M	-$36.90M
Free Cash Flow	$137.8M	$164.9M
YoY Change	-16.43%	11.34%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	dei	Document Period End Date DocumentPeriodEndDate	2015-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0000785161
CY2015Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	91449537	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2014Q2	dei	Entity Public Float EntityPublicFloat	3100000000	USD
	dei	Entity Registrant Name EntityRegistrantName	HEALTHSOUTH CORP
	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2015Q2	hls	Capitalexpenditurespermitted Capitalexpenditurespermitted	200000000	USD
	hls	Percentage Of Net Operating Revenues Workers Compensation PercentageOfNetOperatingRevenuesWorkersCompensation	0.009
	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges	700000	USD
CY2015Q2	hls	Capitalexpenditurespermitted Capitalexpenditurespermitted	350000000	USD
CY2015Q2	hls	Consolidatedcoverageratiominimum Consolidatedcoverageratiominimum	2
CY2014Q2	hls	Equity In Net Income Of Consolidated Affiliates EquityInNetIncomeOfConsolidatedAffiliates	0	USD
	hls	Equity In Net Income Of Consolidated Affiliates EquityInNetIncomeOfConsolidatedAffiliates	0	USD
CY2015Q2	hls	Equity In Net Income Of Consolidated Affiliates EquityInNetIncomeOfConsolidatedAffiliates	0	USD
	hls	Equity In Net Income Of Consolidated Affiliates EquityInNetIncomeOfConsolidatedAffiliates	0	USD
CY2014Q2	hls	Equity Method Investment Summarized Financial Information Operating Expenses EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses	-8200000	USD
	hls	Equity Method Investment Summarized Financial Information Operating Expenses EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses	-19400000	USD
CY2015Q2	hls	Equity Method Investment Summarized Financial Information Operating Expenses EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses	-3800000	USD
	hls	Equity Method Investment Summarized Financial Information Operating Expenses EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses	-7700000	USD
CY2014Q2	hls	Government Class Action And Related Settlements Gain Loss GovernmentClassActionAndRelatedSettlementsGainLoss	-800000	USD
	hls	Government Class Action And Related Settlements Gain Loss GovernmentClassActionAndRelatedSettlementsGainLoss	-800000	USD
CY2015Q2	hls	Government Class Action And Related Settlements Gain Loss GovernmentClassActionAndRelatedSettlementsGainLoss	0	USD
	hls	Government Class Action And Related Settlements Gain Loss GovernmentClassActionAndRelatedSettlementsGainLoss	8000000	USD
CY2014Q2	hls	Gross Realized Gains Losses Availableforsale Securities Sale Proceedsand Increase Decreaseon Derivative GrossRealizedGainsLossesAvailableforsaleSecuritiesSaleProceedsandIncreaseDecreaseonDerivative	0	USD
	hls	Gross Realized Gains Losses Availableforsale Securities Sale Proceedsand Increase Decreaseon Derivative GrossRealizedGainsLossesAvailableforsaleSecuritiesSaleProceedsandIncreaseDecreaseonDerivative	0	USD
CY2015Q2	hls	Gross Realized Gains Losses Availableforsale Securities Sale Proceedsand Increase Decreaseon Derivative GrossRealizedGainsLossesAvailableforsaleSecuritiesSaleProceedsandIncreaseDecreaseonDerivative	2600000	USD
	hls	Gross Realized Gains Losses Availableforsale Securities Sale Proceedsand Increase Decreaseon Derivative GrossRealizedGainsLossesAvailableforsaleSecuritiesSaleProceedsandIncreaseDecreaseonDerivative	2600000	USD
CY2014Q2	hls	Income Loss From Continuing Operations Attributable To Common Shareholders Basic IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic	76700000	USD
	hls	Income Loss From Continuing Operations Attributable To Common Shareholders Basic IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic	121400000	USD
CY2015Q2	hls	Income Loss From Continuing Operations Attributable To Common Shareholders Basic IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic	44200000	USD
	hls	Income Loss From Continuing Operations Attributable To Common Shareholders Basic IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic	85100000	USD
CY2014Q2	hls	Income Loss From Continuing Operations Attributable To Common Shareholders Diluted IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted	81600000	USD
	hls	Income Loss From Continuing Operations Attributable To Common Shareholders Diluted IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted	130600000	USD
CY2015Q2	hls	Income Loss From Continuing Operations Attributable To Common Shareholders Diluted IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted	46800000	USD
	hls	Income Loss From Continuing Operations Attributable To Common Shareholders Diluted IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted	91900000	USD
	hls	Initial Suspension Periodof Medicare Payments InitialSuspensionPeriodofMedicarePayments	P180D
CY2015Q2	hls	Medicare Denials Percentage Collected After Appeal MedicareDenialsPercentageCollectedAfterAppeal	0.63
CY2015Q2	hls	Medicare Denials Percentage Collected After Appeal Including Administrative Law Judge Hearings MedicareDenialsPercentageCollectedAfterAppealIncludingAdministrativeLawJudgeHearings	0.72
CY2014Q2	hls	Net Income Loss Availableto Common Stockholders NetIncomeLossAvailabletoCommonStockholders	80400000	USD
	hls	Net Income Loss Availableto Common Stockholders NetIncomeLossAvailabletoCommonStockholders	125000000	USD
CY2015Q2	hls	Net Income Loss Availableto Common Stockholders NetIncomeLossAvailabletoCommonStockholders	42600000	USD
	hls	Net Income Loss Availableto Common Stockholders NetIncomeLossAvailabletoCommonStockholders	83200000	USD
CY2014Q2	hls	Net Operating Revenues Less Provision For Doubtful Accounts NetOperatingRevenuesLessProvisionForDoubtfulAccounts	595100000	USD
	hls	Net Operating Revenues Less Provision For Doubtful Accounts NetOperatingRevenuesLessProvisionForDoubtfulAccounts	1178800000	USD
CY2015Q2	hls	Net Operating Revenues Less Provision For Doubtful Accounts NetOperatingRevenuesLessProvisionForDoubtfulAccounts	753500000	USD
	hls	Net Operating Revenues Less Provision For Doubtful Accounts NetOperatingRevenuesLessProvisionForDoubtfulAccounts	1482500000	USD
CY2015Q2	hls	Number Of Beds Acquired NumberOfBedsAcquired	50
CY2015Q2	hls	Number Of Beds Acquired NumberOfBedsAcquired	158
CY2015Q2	hls	Number Of General Or Limited Partnerships Limited Liability Companies Or Joint Ventures NumberOfGeneralOrLimitedPartnershipsLimitedLiabilityCompaniesOrJointVentures	8	facilities
CY2015Q2	hls	Number Of Partially Owned Subsidiaries Nonconsolidated NumberOfPartiallyOwnedSubsidiariesNonconsolidated	9	facilities
CY2015Q2	hls	Numberof Beds Acquired Skilled Nursing Facility NumberofBedsAcquiredSkilledNursingFacility	74
CY2014Q4	hls	Numberof Home Health Locations Before Encompass Acquisition NumberofHomeHealthLocationsBeforeEncompassAcquisition	25
CY2014Q2	hls	Occupancy Cost OccupancyCost	10300000	USD
	hls	Occupancy Cost OccupancyCost	20800000	USD
CY2015Q2	hls	Occupancy Cost OccupancyCost	12500000	USD
	hls	Occupancy Cost OccupancyCost	24600000	USD
	hls	Premiumreceivedonbondissuance Premiumreceivedonbondissuance	8000000	USD
CY2007Q4	hls	Option Contract Annual Premium OptionContractAnnualPremium	0.15
CY2007Q4	hls	Option Contract Exercisable OptionContractExercisable	0.30
CY2015Q2	hls	Option Contract Exercisable OptionContractExercisable	0.30
	hls	Ownership Percentage Of Subsidiary Guarantors OwnershipPercentageOfSubsidiaryGuarantors	1.00
CY2014Q2	hls	Percentage Of Net Operating Revenues Managed Care PercentageOfNetOperatingRevenuesManagedCare	0.187
	hls	Percentage Of Net Operating Revenues Managed Care PercentageOfNetOperatingRevenuesManagedCare	0.184
CY2015Q2	hls	Percentage Of Net Operating Revenues Managed Care PercentageOfNetOperatingRevenuesManagedCare	0.178
	hls	Percentage Of Net Operating Revenues Managed Care PercentageOfNetOperatingRevenuesManagedCare	0.180
CY2014Q2	hls	Percentage Of Net Operating Revenues Medicaid PercentageOfNetOperatingRevenuesMedicaid	0.018
	hls	Percentage Of Net Operating Revenues Medicaid PercentageOfNetOperatingRevenuesMedicaid	0.015
CY2015Q2	hls	Percentage Of Net Operating Revenues Medicaid PercentageOfNetOperatingRevenuesMedicaid	0.031
	hls	Percentage Of Net Operating Revenues Medicaid PercentageOfNetOperatingRevenuesMedicaid	0.029
CY2014Q2	hls	Percentage Of Net Operating Revenues Medicare PercentageOfNetOperatingRevenuesMedicare	0.741
	hls	Percentage Of Net Operating Revenues Medicare PercentageOfNetOperatingRevenuesMedicare	0.747
CY2015Q2	hls	Percentage Of Net Operating Revenues Medicare PercentageOfNetOperatingRevenuesMedicare	0.745
	hls	Percentage Of Net Operating Revenues Medicare PercentageOfNetOperatingRevenuesMedicare	0.747
CY2014Q2	hls	Percentage Of Net Operating Revenues Other Income PercentageOfNetOperatingRevenuesOtherIncome	0.016
	hls	Percentage Of Net Operating Revenues Other Income PercentageOfNetOperatingRevenuesOtherIncome	0.016
CY2015Q2	hls	Percentage Of Net Operating Revenues Other Income PercentageOfNetOperatingRevenuesOtherIncome	0.013
	hls	Percentage Of Net Operating Revenues Other Income PercentageOfNetOperatingRevenuesOtherIncome	0.013
CY2014Q2	hls	Percentage Of Net Operating Revenues Other Third Party Payors PercentageOfNetOperatingRevenuesOtherThirdPartyPayors	0.017
	hls	Percentage Of Net Operating Revenues Other Third Party Payors PercentageOfNetOperatingRevenuesOtherThirdPartyPayors	0.016
CY2015Q2	hls	Percentage Of Net Operating Revenues Other Third Party Payors PercentageOfNetOperatingRevenuesOtherThirdPartyPayors	0.018
	hls	Percentage Of Net Operating Revenues Other Third Party Payors PercentageOfNetOperatingRevenuesOtherThirdPartyPayors	0.016
CY2014Q2	hls	Percentage Of Net Operating Revenues Patients PercentageOfNetOperatingRevenuesPatients	0.009
	hls	Percentage Of Net Operating Revenues Patients PercentageOfNetOperatingRevenuesPatients	0.010
CY2015Q2	hls	Percentage Of Net Operating Revenues Patients PercentageOfNetOperatingRevenuesPatients	0.006
	hls	Percentage Of Net Operating Revenues Patients PercentageOfNetOperatingRevenuesPatients	0.006
CY2014Q2	hls	Percentage Of Net Operating Revenues Total PercentageOfNetOperatingRevenuesTotal	1.000
	hls	Percentage Of Net Operating Revenues Total PercentageOfNetOperatingRevenuesTotal	1.000
CY2015Q2	hls	Percentage Of Net Operating Revenues Total PercentageOfNetOperatingRevenuesTotal	1.000
	hls	Percentage Of Net Operating Revenues Total PercentageOfNetOperatingRevenuesTotal	1.000
CY2014Q2	hls	Percentage Of Net Operating Revenues Workers Compensation PercentageOfNetOperatingRevenuesWorkersCompensation	0.012
	hls	Percentage Of Net Operating Revenues Workers Compensation PercentageOfNetOperatingRevenuesWorkersCompensation	0.012
CY2015Q2	hls	Percentage Of Net Operating Revenues Workers Compensation PercentageOfNetOperatingRevenuesWorkersCompensation	0.009
CY2014Q4	hls	Percentage Of Net Patient Service Accounts Receivable PercentageOfNetPatientServiceAccountsReceivable	1.000
CY2015Q2	hls	Percentage Of Net Patient Service Accounts Receivable PercentageOfNetPatientServiceAccountsReceivable	1.000
CY2014Q4	hls	Percentage Of Net Patient Service Accounts Receivable Managed Care And Other Discount Plans PercentageOfNetPatientServiceAccountsReceivableManagedCareAndOtherDiscountPlans	0.185
CY2015Q2	hls	Percentage Of Net Patient Service Accounts Receivable Managed Care And Other Discount Plans PercentageOfNetPatientServiceAccountsReceivableManagedCareAndOtherDiscountPlans	0.203
CY2014Q4	hls	Percentage Of Net Patient Service Accounts Receivable Medicaid PercentageOfNetPatientServiceAccountsReceivableMedicaid	0.018
CY2015Q2	hls	Percentage Of Net Patient Service Accounts Receivable Medicaid PercentageOfNetPatientServiceAccountsReceivableMedicaid	0.025
CY2014Q4	hls	Percentage Of Net Patient Service Accounts Receivable Medicare PercentageOfNetPatientServiceAccountsReceivableMedicare	0.722
CY2015Q2	hls	Percentage Of Net Patient Service Accounts Receivable Medicare PercentageOfNetPatientServiceAccountsReceivableMedicare	0.698
CY2014Q4	hls	Percentage Of Net Patient Service Accounts Receivable Other Third Party Payors PercentageOfNetPatientServiceAccountsReceivableOtherThirdPartyPayors	0.038
CY2015Q2	hls	Percentage Of Net Patient Service Accounts Receivable Other Third Party Payors PercentageOfNetPatientServiceAccountsReceivableOtherThirdPartyPayors	0.042
CY2014Q4	hls	Percentage Of Net Patient Service Accounts Receivable Patients PercentageOfNetPatientServiceAccountsReceivablePatients	0.018
CY2015Q2	hls	Percentage Of Net Patient Service Accounts Receivable Patients PercentageOfNetPatientServiceAccountsReceivablePatients	0.013
CY2014Q4	hls	Percentage Of Net Patient Service Accounts Receivable Workers Compensation PercentageOfNetPatientServiceAccountsReceivableWorkersCompensation	0.019
CY2015Q2	hls	Percentage Of Net Patient Service Accounts Receivable Workers Compensation PercentageOfNetPatientServiceAccountsReceivableWorkersCompensation	0.019
	hls	Premium Paid On Redemption Of Bonds PremiumPaidOnRedemptionOfBonds	0	USD
	hls	Premium Paid On Redemption Of Bonds PremiumPaidOnRedemptionOfBonds	11800000	USD
	hls	Premiumreceivedonbondissuance Premiumreceivedonbondissuance	0	USD
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2500000	shares
CY2014Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	22200000	USD
CY2015Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	26100000	USD
CY2014Q4	us-gaap	Assets Assets	3408800000	USD
CY2015Q2	us-gaap	Assets Assets	3469500000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	686600000	USD
CY2015Q2	us-gaap	Assets Current AssetsCurrent	712400000	USD
CY2015Q2	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax	600000	USD
CY2015Q2	us-gaap	Available For Sale Securities Equity Securities AvailableForSaleSecuritiesEquitySecurities	7400000	USD
CY2015Q2	us-gaap	Available For Sale Securities Gross Realized Gains Losses Sale Proceeds AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds	600000	USD
	us-gaap	Available For Sale Securities Gross Realized Gains Losses Sale Proceeds AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds	600000	USD
CY2014Q2	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	83600000	USD
	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	129600000	USD
CY2015Q2	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	42700000	USD
CY2014Q2	hls	Professional Fees Accounting Tax And Legal ProfessionalFeesAccountingTaxAndLegal	2000000	USD
	hls	Professional Fees Accounting Tax And Legal ProfessionalFeesAccountingTaxAndLegal	3600000	USD
CY2015Q2	hls	Professional Fees Accounting Tax And Legal ProfessionalFeesAccountingTaxAndLegal	100000	USD
	hls	Professional Fees Accounting Tax And Legal ProfessionalFeesAccountingTaxAndLegal	2300000	USD
CY2015Q2	hls	Seniorsecuredleverageratiomaximum Seniorsecuredleverageratiomaximum	1.75
	hls	Stock Issued During Period Value Conversionof Preferred Stock StockIssuedDuringPeriodValueConversionofPreferredStock	93200000	USD
	hls	Treasury Stock Reacquired TreasuryStockReacquired	9700000	USD
	hls	Treasury Stock Reacquired TreasuryStockReacquired	16600000	USD
	hls	Treasury Stock Value Acquired Cost Method Common Stock TreasuryStockValueAcquiredCostMethodCommonStock	43100000	USD
CY2014Q2	hls	Undistributed Earnings From Discontinued Operations Allocatedto Participating Securities UndistributedEarningsFromDiscontinuedOperationsAllocatedtoParticipatingSecurities	-100000	USD
	hls	Undistributed Earnings From Discontinued Operations Allocatedto Participating Securities UndistributedEarningsFromDiscontinuedOperationsAllocatedtoParticipatingSecurities	-100000	USD
CY2015Q2	hls	Undistributed Earnings From Discontinued Operations Allocatedto Participating Securities UndistributedEarningsFromDiscontinuedOperationsAllocatedtoParticipatingSecurities	0	USD
	hls	Undistributed Earnings From Discontinued Operations Allocatedto Participating Securities UndistributedEarningsFromDiscontinuedOperationsAllocatedtoParticipatingSecurities	0	USD
	hls	Warrants Exercised Value WarrantsExercisedValue	6300000	USD
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	53400000	USD
CY2015Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	60000000	USD
CY2014Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	323200000	USD
CY2015Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	351800000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	14300000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	14900000	USD
	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	79400000	USD
	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	83800000	USD
	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	85200000	USD
CY2014Q2	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	625600000	USD
	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	1237000000	USD
CY2015Q2	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	770400000	USD
	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	1531900000	USD
	us-gaap	Business Combination Pro Forma Information Earnings Or Loss Of Acquiree Since Acquisition Date Actual BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual	-1100000	USD
	us-gaap	Business Combination Pro Forma Information Revenue Of Acquiree Since Acquisition Date Actual BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual	15700000	USD
	us-gaap	Business Combination Step Acquisition Equity Interest In Acquiree Remeasurement Gain BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain	27200000	USD
	us-gaap	Business Combination Step Acquisition Equity Interest In Acquiree Remeasurement Gain BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain	0	USD
CY2014Q4	us-gaap	Capital Lease Obligations CapitalLeaseObligations	86700000	USD
CY2015Q2	us-gaap	Capital Lease Obligations CapitalLeaseObligations	84200000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	64500000	USD
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	65800000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	66700000	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	45500000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1300000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-21200000	USD
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-1200000	USD
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-300000	USD
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q2	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.18
	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.36
CY2015Q2	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.21
	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.42
CY2014Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	83200000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	130000000	USD
CY2015Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	43000000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	85600000	USD
CY2014Q2	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	14800000	USD
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	29600000	USD
CY2015Q2	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	17300000	USD
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	33800000	USD
CY2014Q2	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	98000000	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	159600000	USD
CY2015Q2	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	60300000	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	119400000	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	93200000	USD
CY2014Q2	us-gaap	Costs And Expenses CostsAndExpenses	467500000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	934900000	USD
CY2015Q2	us-gaap	Costs And Expenses CostsAndExpenses	615100000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	1223600000	USD
CY2014Q4	us-gaap	Debt And Capital Lease Obligations DebtAndCapitalLeaseObligations	2131600000	USD
CY2015Q2	us-gaap	Debt And Capital Lease Obligations DebtAndCapitalLeaseObligations	2125800000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	62700000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	55600000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Liabilities Net Current DeferredTaxAssetsLiabilitiesNetCurrent	188400000	USD
CY2015Q2	us-gaap	Deferred Tax Assets Liabilities Net Current DeferredTaxAssetsLiabilitiesNetCurrent	188400000	USD
CY2015Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	268100000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	188400000	USD
CY2015Q2	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	188400000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	129400000	USD
CY2015Q2	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	79700000	USD
CY2015Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	23000000	USD
CY2014Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	26400000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	52800000	USD
CY2015Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	32700000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	64600000	USD
CY2014Q4	us-gaap	Derivative Assets Noncurrent DerivativeAssetsNoncurrent	9900000	USD
CY2014Q2	us-gaap	Derivative Gain On Derivative DerivativeGainOnDerivative	6700000	USD
	us-gaap	Derivative Gain On Derivative DerivativeGainOnDerivative	6700000	USD
	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	200000	USD
CY2015Q2	us-gaap	Derivative Gain On Derivative DerivativeGainOnDerivative	2000000	USD
	us-gaap	Derivative Gain On Derivative DerivativeGainOnDerivative	2000000	USD
	us-gaap	Derivative Loss On Derivative DerivativeLossOnDerivative	400000	USD
	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	32000000	USD
	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	38000000	USD
CY2014Q2	us-gaap	Dividends Preferred Stock DividendsPreferredStock	1500000	USD
	us-gaap	Dividends Preferred Stock DividendsPreferredStock	3100000	USD
CY2015Q2	us-gaap	Dividends Preferred Stock DividendsPreferredStock	0	USD
	us-gaap	Dividends Preferred Stock DividendsPreferredStock	1600000	USD
	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	3100000	USD
	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	1600000	USD
CY2014Q4	us-gaap	Due From Related Parties Noncurrent DueFromRelatedPartiesNoncurrent	0	USD
CY2015Q2	us-gaap	Due From Related Parties Noncurrent DueFromRelatedPartiesNoncurrent	0	USD
CY2014Q4	us-gaap	Due To Related Parties Noncurrent DueToRelatedPartiesNoncurrent	0	USD
CY2015Q2	us-gaap	Due To Related Parties Noncurrent DueToRelatedPartiesNoncurrent	0	USD
CY2014Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.93
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.44
CY2015Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.47
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.94
CY2014Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.85
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.33
CY2015Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.45
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.89
	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	14300000	USD
	us-gaap	Equity Method Investment Dividends Or Distributions EquityMethodInvestmentDividendsOrDistributions	6500000	USD
	us-gaap	Equity Method Investment Dividends Or Distributions EquityMethodInvestmentDividendsOrDistributions	3700000	USD
CY2014Q2	us-gaap	Equity Method Investment Summarized Financial Information Income Loss From Continuing Operations Before Extraordinary Items EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItems	5500000	USD
	us-gaap	Equity Method Investment Summarized Financial Information Income Loss From Continuing Operations Before Extraordinary Items EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItems	24000000	USD
CY2015Q2	us-gaap	Equity Method Investment Summarized Financial Information Income Loss From Continuing Operations Before Extraordinary Items EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItems	4800000	USD
	us-gaap	Equity Method Investment Summarized Financial Information Income Loss From Continuing Operations Before Extraordinary Items EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItems	8700000	USD
CY2014Q2	us-gaap	Equity Method Investment Summarized Financial Information Net Income Loss EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss	5500000	USD
	us-gaap	Equity Method Investment Summarized Financial Information Net Income Loss EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss	24000000	USD
CY2015Q2	us-gaap	Equity Method Investment Summarized Financial Information Net Income Loss EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss	4800000	USD
	us-gaap	Equity Method Investment Summarized Financial Information Net Income Loss EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss	8700000	USD
CY2014Q2	us-gaap	Equity Method Investment Summarized Financial Information Revenue EquityMethodInvestmentSummarizedFinancialInformationRevenue	15000000	USD
	us-gaap	Equity Method Investment Summarized Financial Information Revenue EquityMethodInvestmentSummarizedFinancialInformationRevenue	36300000	USD
CY2015Q2	us-gaap	Equity Method Investment Summarized Financial Information Revenue EquityMethodInvestmentSummarizedFinancialInformationRevenue	8900000	USD
	us-gaap	Equity Method Investment Summarized Financial Information Revenue EquityMethodInvestmentSummarizedFinancialInformationRevenue	17100000	USD
CY2014Q2	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges	-1700000	USD
	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges	-3000000	USD
CY2015Q2	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges	-800000	USD
CY2014Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2015Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1200000	USD
CY2015Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-18800000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-20000000	USD
CY2014Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	30200000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	60900000	USD
CY2015Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	32100000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	66700000	USD
CY2014Q4	us-gaap	Goodwill Goodwill	1084000000	USD
CY2015Q2	us-gaap	Goodwill Goodwill	1097500000	USD
CY2014Q2	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	604400000	USD
	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	1195600000	USD
CY2015Q2	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	764400000	USD
	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	1505000000	USD
CY2014Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	79300000	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	126100000	USD
CY2015Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	44500000	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	87300000	USD
CY2014Q2	us-gaap	Income Loss From Continuing Operations Attributable To Noncontrolling Entity IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity	14800000	USD
	us-gaap	Income Loss From Continuing Operations Attributable To Noncontrolling Entity IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity	29600000	USD
CY2015Q2	us-gaap	Income Loss From Continuing Operations Attributable To Noncontrolling Entity IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity	17300000	USD
	us-gaap	Income Loss From Continuing Operations Attributable To Noncontrolling Entity IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity	33800000	USD
CY2014Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	130600000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	225000000	USD
CY2015Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	94000000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	183600000	USD
CY2014Q2	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	94100000	USD
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	155700000	USD
CY2015Q2	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	61800000	USD
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	121100000	USD
CY2014Q2	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.89
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	1.40
CY2015Q2	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.49
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.96
CY2014Q2	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.81
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	1.29
CY2015Q2	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.47
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.91
CY2014Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	3800000	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	3700000	USD
CY2015Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-1600000	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-1900000	USD
CY2014Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	3800000	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	3700000	USD
CY2015Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-1600000	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-1900000	USD
CY2014Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.04
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.04
CY2015Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.02
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.02
CY2015Q2	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	8200000	shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	8200000	shares
CY2014Q2	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	3200000	shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	3200000	shares
CY2015Q2	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	800000	shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	2000000	shares
CY2014Q2	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2500000	shares
CY2014Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0.04
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0.04
CY2015Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.02
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.02
CY2014Q2	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	2600000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	6900000	USD
CY2015Q2	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	2300000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	3900000	USD
CY2014Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	36500000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	69300000	USD
CY2015Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	32200000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	62500000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2700000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1700000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	35600000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	62100000	USD
	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	-15100000	USD
	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	-23600000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-8400000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	6500000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-4900000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-10700000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-6500000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-13100000	USD
CY2014Q2	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	8200000	shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	8100000	shares
CY2015Q2	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2700000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2700000	shares
CY2014Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	306100000	USD
CY2015Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	325500000	USD
CY2014Q2	us-gaap	Interest And Debt Expense InterestAndDebtExpense	27800000	USD
	us-gaap	Interest And Debt Expense InterestAndDebtExpense	55700000	USD
CY2015Q2	us-gaap	Interest And Debt Expense InterestAndDebtExpense	30900000	USD
	us-gaap	Interest And Debt Expense InterestAndDebtExpense	62700000	USD
CY2014Q2	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	2300000	USD
	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	4500000	USD
CY2015Q2	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	2300000	USD
	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	4600000	USD
CY2014Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	9400000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
	us-gaap	Management Fees Revenue ManagementFeesRevenue	0	USD
CY2015Q2	us-gaap	Management Fees Revenue ManagementFeesRevenue	0	USD
	us-gaap	Management Fees Revenue ManagementFeesRevenue	0	USD
CY2014Q4	us-gaap	Minority Interest MinorityInterest	146300000	USD
CY2015Q2	us-gaap	Minority Interest MinorityInterest	158800000	USD
	us-gaap	Minority Interest Change In Redemption Value MinorityInterestChangeInRedemptionValue	-6800000	USD
	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	22300000	USD
	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	23400000	USD
CY2015Q2	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	9500000	USD
CY2014Q2	us-gaap	Labor And Related Expense LaborAndRelatedExpense	285300000	USD
	us-gaap	Labor And Related Expense LaborAndRelatedExpense	571400000	USD
CY2015Q2	us-gaap	Labor And Related Expense LaborAndRelatedExpense	401800000	USD
	us-gaap	Labor And Related Expense LaborAndRelatedExpense	786900000	USD
CY2014Q4	us-gaap	Liabilities Liabilities	2611400000	USD
CY2015Q2	us-gaap	Liabilities Liabilities	2606300000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3408800000	USD
CY2015Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3469500000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	364300000	USD
CY2015Q2	us-gaap	Liabilities Current LiabilitiesCurrent	364600000	USD
CY2014Q4	us-gaap	Line Of Credit LineOfCredit	325000000	USD
CY2015Q2	us-gaap	Line Of Credit LineOfCredit	153000000	USD
CY2014Q4	us-gaap	Loans Payable To Bank LoansPayableToBank	450000000	USD
CY2014Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	2110800000	USD
CY2015Q2	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	2104400000	USD
CY2014Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	20800000	USD
CY2015Q2	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	21400000	USD
CY2014Q2	us-gaap	Management Fees Revenue ManagementFeesRevenue	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-126800000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-99400000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-107000000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-126700000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	235100000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	204900000	USD
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	83100000	USD
	us-gaap	Net Income Loss NetIncomeLoss	129800000	USD
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	42900000	USD
	us-gaap	Net Income Loss NetIncomeLoss	85400000	USD
CY2014Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	14800000	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	29600000	USD
CY2015Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	17300000	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	33800000	USD
CY2014Q2	us-gaap	Net Income Loss Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossAttributableToNonredeemableNoncontrollingInterest	13200000	USD
	us-gaap	Net Income Loss Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossAttributableToNonredeemableNoncontrollingInterest	26000000	USD
CY2015Q2	us-gaap	Net Income Loss Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossAttributableToNonredeemableNoncontrollingInterest	13800000	USD
	us-gaap	Net Income Loss Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossAttributableToNonredeemableNoncontrollingInterest	27400000	USD
CY2014Q2	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	1600000	USD
	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	3600000	USD
CY2015Q2	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	3500000	USD
	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	6400000	USD
CY2014Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	81600000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	126700000	USD
CY2015Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	42900000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	83800000	USD
CY2014Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	85400000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	134300000	USD
CY2015Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	45200000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	90000000	USD
	us-gaap	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest	155800000	USD
	us-gaap	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest	112800000	USD
	us-gaap	Noncontrolling Interest Increase From Business Combination NoncontrollingInterestIncreaseFromBusinessCombination	14000000	USD
CY2015Q2	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	485000000	USD
CY2014Q4	us-gaap	Other Assets Current OtherAssetsCurrent	108300000	USD
CY2015Q2	us-gaap	Other Assets Current OtherAssetsCurrent	126700000	USD
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	183000000	USD
CY2015Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	191600000	USD
CY2014Q2	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	100000	USD
CY2015Q2	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	200000	USD
	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	300000	USD
CY2014Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	100000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	200000	USD
CY2015Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	100000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	200000	USD
CY2014Q2	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	500000	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	500000	USD
CY2015Q2	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	600000	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	600000	USD
CY2014Q2	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0	USD
	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0	USD
CY2015Q2	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	100000	USD
	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	100000	USD
CY2014Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	600000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	700000	USD
CY2015Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	800000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	900000	USD
CY2014Q2	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	86300000	USD
	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	170800000	USD
CY2015Q2	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	104200000	USD
	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	207400000	USD
CY2014Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	290100000	USD
CY2015Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	283200000	USD
CY2014Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	136300000	USD
CY2015Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	137300000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-6100000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-11000000	USD
CY2014Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	28200000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	29900000	USD
CY2015Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3000000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3500000	USD
CY2014Q4	us-gaap	Other Notes Payable OtherNotesPayable	41600000	USD
CY2015Q2	us-gaap	Other Notes Payable OtherNotesPayable	40400000	USD
	us-gaap	Partners Capital Account Contributions PartnersCapitalAccountContributions	8600000	USD
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-2900000	USD
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	600000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	43100000	USD
	us-gaap	Payments For Software PaymentsForSoftware	11000000	USD
	us-gaap	Payments For Software PaymentsForSoftware	15200000	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	13900000	USD
	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	31600000	USD
	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	37100000	USD
	us-gaap	Payments Of Dividends Minority Interest PaymentsOfDividendsMinorityInterest	25400000	USD
	us-gaap	Payments Of Dividends Minority Interest PaymentsOfDividendsMinorityInterest	26200000	USD
	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	3100000	USD
	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	3100000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	15900000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	77700000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	89500000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	46300000	USD
CY2014	us-gaap	Prior Period Reclassification Adjustment PriorPeriodReclassificationAdjustment	-64300000	USD
	us-gaap	Prior Period Reclassification Adjustment PriorPeriodReclassificationAdjustment	-64300000	USD
	us-gaap	Proceeds From Issuance Of Senior Long Term Debt ProceedsFromIssuanceOfSeniorLongTermDebt	0	USD
	us-gaap	Proceeds From Issuance Of Senior Long Term Debt ProceedsFromIssuanceOfSeniorLongTermDebt	700000000	USD
	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	65000000	USD
	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	270000000	USD
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	6400000	USD
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-1000000	USD
	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	0	USD
	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	0	USD
CY2014Q2	us-gaap	Profit Loss ProfitLoss	97900000	USD
	us-gaap	Profit Loss ProfitLoss	159400000	USD
CY2015Q2	us-gaap	Profit Loss ProfitLoss	60200000	USD
	us-gaap	Profit Loss ProfitLoss	119200000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1019700000	USD
CY2015Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1062800000	USD
CY2014Q2	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	9300000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	16800000	USD
CY2015Q2	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	10900000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	22500000	USD
CY2014Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	84700000	USD
CY2015Q2	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	98500000	USD
CY2014Q4	us-gaap	Redeemable Noncontrolling Interest Equity Fair Value RedeemableNoncontrollingInterestEquityFairValue	84700000	USD
CY2015Q2	us-gaap	Redeemable Noncontrolling Interest Equity Fair Value RedeemableNoncontrollingInterestEquityFairValue	98500000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	546100000	USD
	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	95000000	USD
	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	442000000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	14300000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	15600000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	6300000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	2000000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	473200000	USD
CY2015Q2	us-gaap	Stockholders Equity StockholdersEquity	605900000	USD
CY2013Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	468700000	USD
CY2014Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	555400000	USD
CY2014Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	619500000	USD
CY2015Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	764700000	USD
	us-gaap	Stockholders Equity Other StockholdersEquityOther	-200000	USD
	us-gaap	Stockholders Equity Other StockholdersEquityOther	-100000	USD
CY2014Q2	us-gaap	Supplies Expense SuppliesExpense	27800000	USD
	us-gaap	Supplies Expense SuppliesExpense	55400000	USD
CY2015Q2	us-gaap	Supplies Expense SuppliesExpense	31700000	USD
	us-gaap	Supplies Expense SuppliesExpense	63100000	USD
CY2014Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	93200000	USD
CY2015Q2	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	USD
CY2014Q2	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	-1100000	USD
	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	-1600000	USD
CY2015Q2	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	-300000	USD
	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	-600000	USD
CY2014Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	900000	USD
CY2015Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2400000	USD
	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	1500000	USD
CY2014Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	900000	USD
CY2015Q2	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	2400000	USD
CY2014Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	100600000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	100800000	shares
CY2015Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	101500000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	101300000	shares
CY2014Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	86700000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	87000000	shares
CY2015Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	89800000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	88400000	shares
	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contingencies and Other Commitments</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We operate in a highly regulated and litigious industry. As a result, various lawsuits, claims, and legal and regulatory proceedings have been and can be expected to be instituted or asserted against us. The resolution of any such lawsuits, claims, or legal and regulatory proceedings could materially and adversely affect our financial position, results of operations, and cash flows in a given period. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">General Medicine Action—</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On August 16, 2004, General Medicine, P.C. filed a lawsuit in the Circuit Court of Jefferson County, Alabama (the “Alabama Action”) against us captioned </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">General Medicine, P.C. v. HealthSouth Corp.</font><font style="font-family:inherit;font-size:10pt;"> seeking the recovery of allegedly fraudulent transfers involving assets of Horizon/CMS Healthcare Corporation, a former subsidiary of HealthSouth. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General Medicine’s underlying claim against Horizon/CMS originates from a services contract entered into in 1995 between General Medicine and Horizon/CMS whereby General Medicine agreed to provide medical director services to skilled nursing facilities owned by Horizon/CMS for a term of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three years</font><font style="font-family:inherit;font-size:10pt;">. Horizon/CMS terminated the agreement for cause six months after it was executed, and General Medicine then initiated a lawsuit against Horizon/CMS in the United States District Court for the Eastern District of Michigan in 1996 (the “Michigan Action”). General Medicine’s complaint in the Michigan Action alleged that Horizon/CMS breached the services contract by wrongfully terminating General Medicine. We acquired Horizon/CMS in 1997 and sold it to Meadowbrook Healthcare, Inc. in 2001 pursuant to a stock purchase agreement. In 2004, Meadowbrook, without the knowledge of HealthSouth, consented to the entry of a final judgment in the Michigan Action in favor of General Medicine against Horizon/CMS for the alleged wrongful termination of the contract with General Medicine in the amount of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$376 million</font><font style="font-family:inherit;font-size:10pt;"> (the “Consent Judgment”). The </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$376 million</font><font style="font-family:inherit;font-size:10pt;"> damages figure was unilaterally selected by General Medicine and was not tested or opposed by Meadowbrook. Additionally, the settlement agreement (the “Settlement”) used as the basis for the Consent Judgment provided that Meadowbrook would pay only </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$300,000</font><font style="font-family:inherit;font-size:10pt;"> to General Medicine to settle the Michigan Action and that General Medicine would seek to recover the remaining balance of the Consent Judgment solely from us. We were not a party to the Michigan Action, the Settlement negotiated by Meadowbrook, or the Consent Judgment. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The complaint filed by General Medicine against us in the Alabama Action alleged that while Horizon/CMS was our wholly owned subsidiary, General Medicine was an existing creditor of Horizon/CMS by virtue of the breach of contract claim underlying the Settlement. The complaint also alleged we caused Horizon/CMS to transfer its assets to us for less than a reasonably equivalent value or, in the alternative, with the actual intent to defraud creditors of Horizon/CMS, including General Medicine, in violation of the Alabama Uniform Fraudulent Transfer Act. General Medicine further alleged in its amended complaint that we were liable for the Consent Judgment despite not being a party to it because as Horizon/CMS’s parent we failed to observe corporate formalities in our operation and ownership of Horizon/CMS, misused our control of Horizon/CMS, stripped assets from Horizon/CMS, and engaged in other conduct which amounted to a fraud on Horizon/CMS’s creditors. General Medicine requested relief including recovery of the unpaid amount of the Consent Judgment, the avoidance of the subject transfers of assets, attachment of the assets transferred to us, appointment of a receiver over the transferred properties, and a monetary judgment for the value of properties transferred. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We denied liability to General Medicine and asserted defenses and a counterclaim against General Medicine that the Consent Judgment was the product of collusion by General Medicine and Meadowbrook. Consequently, we asserted that the Consent Judgment was not evidence of a legitimate debt owed by Horizon/CMS to General Medicine that was collectible from HealthSouth under any theory of liability.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The trial in the Alabama Action began on March 9, 2015. On March 22, 2015, we entered into an agreement with General Medicine to settle the Alabama Action</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">. </font><font style="font-family:inherit;font-size:10pt;">Although the specific terms of this settlement agreement are confidential, both parties agreed to dismiss with prejudice the lawsuit pending in the Circuit Court of Jefferson County, Alabama and to release all claims between the parties. In exchange for General Medicine’s release, we agreed to pay an amount of cash that is not material.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other Litigation—</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have been named as a defendant in a lawsuit filed March 28, 2003 by several individual stockholders in the Circuit Court of Jefferson County, Alabama, captioned </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Nichols v. HealthSouth Corp</font><font style="font-family:inherit;font-size:10pt;">. The plaintiffs allege that we, some of our former officers, and our former investment bank engaged in a scheme to overstate and misrepresent our earnings and financial position. The plaintiffs are seeking compensatory and punitive damages. This case was consolidated with the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Tucker</font><font style="font-family:inherit;font-size:10pt;"> case for discovery and other pretrial purposes and was stayed in the Circuit Court on August 8, 2005. The plaintiffs filed an amended complaint on November 9, 2010 to which we responded with a motion to dismiss filed on December 22, 2010. During a hearing on February 24, 2012, plaintiffs’ counsel indicated his intent to dismiss certain claims against us. Instead, on March 9, 2012, the plaintiffs amended their complaint to include additional securities fraud claims against HealthSouth and add several former officers to the lawsuit. On September 12, 2012, the plaintiffs further amended their complaint to request certification as a class action. One of those named officers has repeatedly attempted to remove the case to federal district court, most recently on December 11, 2012. We filed our latest motion to remand the case back to state court on January 10, 2013. On September 27, 2013, the federal court remanded the case back to state court. On November 25, 2014, the plaintiffs filed another amended complaint to assert new allegations relating to the time period of 1997 to 2002. On December 10, 2014, we filed a motion to dismiss on the grounds the plaintiffs lack standing because their claims are derivative in nature, and the claims are time-barred by the statute of limitations. A hearing on our motion has not yet been set.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We intend to vigorously defend ourselves in this case. Based on the stage of litigation, review of the current facts and circumstances as we understand them, the nature of the underlying claim, the results of the proceedings to date, and the nature and scope of the defense we continue to mount, we do not believe an adverse judgment or settlement is probable in this matter, and it is also not possible to estimate the amount of loss, if any, or range of possible loss that might result from an adverse judgment or settlement of this case.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Governmental Inquiries and Investigations—</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 24, 2011, we received a document subpoena addressed to HealthSouth Hospital of Houston, a long-term acute care hospital (“LTCH”) we closed in August 2011, and issued from the Dallas, Texas office of the HHS-OIG. The subpoena stated it was in connection with an investigation of possible false or otherwise improper claims submitted to Medicare and Medicaid and requested documents and materials relating to patient admissions, length of stay, and discharge matters at this closed LTCH. We furnished the documents requested and have heard nothing from the HHS-OIG since December 2012.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 4, 2013, we received document subpoenas from an office of the HHS-OIG addressed to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">four</font><font style="font-family:inherit;font-size:10pt;"> of our hospitals. Those subpoenas also requested complete copies of medical records for </font><font style="font-family:inherit;font-size:10pt;">100</font><font style="font-family:inherit;font-size:10pt;"> patients treated at each of those hospitals between September 2008 and June 2012. The investigation is being conducted by the United States Department of Justice (the “DOJ”). On April 24, 2014, we received document subpoenas relating to an additional </font><font style="font-family:inherit;font-size:10pt;">seven</font><font style="font-family:inherit;font-size:10pt;"> of our hospitals. The new subpoenas reference substantially similar investigation subject matter as the original subpoenas and request materials from the period January 2008 through December 2013. </font><font style="font-family:inherit;font-size:10pt;">Two</font><font style="font-family:inherit;font-size:10pt;"> of the four hospitals addressed in the original set of subpoenas have received supplemental subpoenas to cover this new time period. The most recent subpoenas do not include requests for specific patient files. However, in February 2015, the DOJ requested the voluntary production of the medical records of an additional </font><font style="font-family:inherit;font-size:10pt;">70</font><font style="font-family:inherit;font-size:10pt;"> patients, some of whom were treated in hospitals not subject to the subpoenas, and we provided these records. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All of the subpoenas are in connection with an investigation of alleged improper or fraudulent claims submitted to Medicare and Medicaid and request documents and materials relating to practices, procedures, protocols and policies, of certain pre- and post-admissions activities at these hospitals including, among other things, marketing functions, pre-admission screening, post-admission physician evaluations, patient assessment instruments, individualized patient plans of care, and compliance with the Medicare </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">60%</font><font style="font-family:inherit;font-size:10pt;"> rule. Under the Medicare rule commonly referred to as the “</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">60%</font><font style="font-family:inherit;font-size:10pt;"> rule,” an inpatient rehabilitation hospital must treat </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">60%</font><font style="font-family:inherit;font-size:10pt;"> or more of its patients from at least one of a specified list of medical conditions in order to be reimbursed at the inpatient rehabilitation hospital payment rates, rather than at the lower acute care hospital payment rates. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are cooperating fully with the DOJ in connection with these subpoenas and are currently unable to predict the timing or outcome of the related investigations. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other Matters—</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The False Claims Act, 18 U.S.C. § 287, allows private citizens, called “relators,” to institute civil proceedings alleging violations of the False Claims Act. These </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</font><font style="font-family:inherit;font-size:10pt;"> cases are generally sealed by the court at the time of filing. The only parties typically privy to the information contained in the complaint are the relator, the federal government, and the presiding court. It is possible that </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</font><font style="font-family:inherit;font-size:10pt;"> lawsuits have been filed against us and that those suits remain under seal or that we are unaware of such filings or prevented by existing law, court order, or agreement with the government from discussing or disclosing the filing of such suits. We may be subject to liability under one or more undisclosed </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</font><font style="font-family:inherit;font-size:10pt;"> cases brought pursuant to the False Claims Act.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">It is our obligation as a participant in Medicare and other federal healthcare programs to routinely conduct audits and reviews of the accuracy of our billing systems and other regulatory compliance matters. As a result of these reviews, we have made, and will continue to make, disclosures to the HHS-OIG and the United States Centers for Medicare and Medicaid Services relating to amounts we suspect represent over-payments from these programs, whether due to inaccurate billing or otherwise. Some of these disclosures have resulted in, or may result in, HealthSouth refunding amounts to Medicare or other federal healthcare programs.</font></div></div>

Files In Submission

Name	View Source	Status
0000785161-15-000069-index-headers.html	Edgar Link	pending
0000785161-15-000069-index.html	Edgar Link	pending
0000785161-15-000069.txt	Edgar Link	pending
0000785161-15-000069-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
hls-20150331.xml	Edgar Link	completed
hls-20150331.xsd	Edgar Link	pending
hls-20150331_cal.xml	Edgar Link	unprocessable
hls-20150331_def.xml	Edgar Link	unprocessable
hls-20150331_lab.xml	Edgar Link	unprocessable
hls-20150331_pre.xml	Edgar Link	unprocessable
hls10q63015.htm	Edgar Link	pending
hls10q63015ex311.htm	Edgar Link	pending
hls10q63015ex312.htm	Edgar Link	pending
hls10q63015ex321.htm	Edgar Link	pending
hls10q63015ex322.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EHC
Encompass Health Corp Stock $ehc

2015 Q2 Form 10-Q Financial Statement

#000078516115000069 Filed on July 30, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EHC Encompass Health Corp Stock $ehc

2015 Q2 Form 10-Q Financial Statement

#000078516115000069 Filed on July 30, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EHC
Encompass Health Corp Stock $ehc